Research programme: diabetes mellitus therapeutics - ImmuPharma

Drug Profile

Research programme: diabetes mellitus therapeutics - ImmuPharma

Alternative Names: Gastric inhibitory peptide - ImmuPharma; GIP - ImmuPharma; GLP1 - ImmuPharma; Glucagon-like peptide 1 - ImmuPharma

Latest Information Update: 02 Jul 2014

Price : $50

At a glance

  • Originator ImmuPharma
  • Developer CNRS; ImmuPharma; University of Bordeaux
  • Class Peptide hormones; Recombinant proteins
  • Mechanism of Action Gastric inhibitory polypeptide stimulants; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Diabetes mellitus

Most Recent Events

  • 27 Jun 2014 Early research in Diabetes mellitus in France (unspecified route)
  • 27 Jun 2014 Early research in Diabetes mellitus in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top